Processa Pharmaceuticals ... (PCSA)
NasdaqCM: PCSA
· Precio en tiempo real · USD
2.56
-0.07 (-2.66%)
Al cierre: Aug 12, 2026, 3:59 PM
Processa Pharmaceuticals Inc. (PCSA) Stock Price, Analysis & Data
-2.66% (1D)
| Precio de compra | 0.05 |
| Capitalización de mercado | 8.58M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -14.11M |
| Beta | 0.96 |
| EPS (TTM) | -3.96 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -0.68 |
| P/B (TTM) | 2.70 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 2.62 |
| Volumen | 82,047 |
| Volumen medio (20D) | 257,429 |
| Abierto | 2.61 |
| Anterior Cerrar | 2.63 |
| Rango del día | 2.48 - 2.67 |
| Rango de 52 semanas | 1.67 - 14.25 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS642...
Industria Biotechnology
Sector Healthcare
IPO Fecha Mar 7, 2014
Empleados 12
Bolsa de Valores NasdaqCM
Símbolo bursátil PCSA
Sitio web https://www.processapharmaceuticals.com
Desempeño financiero
En 2025, los ingresos de Processa Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -13.56M, un aumento de 14.46%.
Estados financierosSorpresa de resultados
Processa Pharmaceuticals ha publicado sus resultados trimestrales en Nov 6, 2025:
